摘要
目的探讨利拉鲁肽联合二甲双胍治疗老年2型糖尿病患者的临床效果。方法 80例老年2型糖尿病患者,随机分为试验组和对照组,各40例。对照组采用二甲双胍进行治疗,试验组在对照组基础采用利拉鲁肽进行治疗,比较两组患者空腹血糖(FPG)、餐后2 h血糖(2 hPG)、糖化血红蛋白(HbA1c)及不良反应发生情况。结果治疗后,试验组空腹血糖(6.02±2.30)mmol/L、餐后2 h血糖(6.59±2.30)mmol/L、糖化血红蛋白(6.01±1.00)%均低于对照组的(7.36±2.10)mmol/L、(7.69±2.10)mmol/L、(6.50±1.10)%,差异有统计学意义(P<0.05)。试验组不良反应发生率为2.50%,明显低于对照组的15.00%,差异有统计学意义(P<0.05)。结论采用利拉鲁肽联合二甲双胍对老年2型糖尿病患者进行治疗,其有效性及安全性高,值得在临床推广。
Objective To discuss the clinical effect of liraglutide combined with metformin in the treatment of senile type 2 diabetes mellitus. Methods A total of 80 senile patients with type 2 diabetes mellitus were randomly divided into experimental group and control group, with 40 cases in each group. The control group was treated with metformin, and the experimental group was treated with liraglutide on the basis of the control group. Comparison were made on fasting blood glucose(FPG), postprandial 2 h blood glucose(2-hPG), glycosylated hemoglobin(HbA1c) and incidence of adverse reactions between the two groups. Results After treatment, the experimental group had lower fasting blood glucose as(6.02±2.30) mmol/L, postprandial 2 h blood glucose as(6.59±2.30) mmol/L and glycosylated hemoglobin as(6.01±1.00)% than(7.36±2.10) mmol/L,(7.69±2.10) mmol/L and(6.50±1.10)% in the control group, and the difference was statistically significant(P<0.05). The experimental group had obviously lower incidence of adverse reactions as 2.50% than 15.00% in the control group, and the difference was statistically significant(P<0.05). Conclusion Liraglutide combined with metformin shows high effectiveness and safety in the treatment of elderly patients with type 2 diabetes mellitus, and it is worthy of clinical promotion.
作者
李芳
LI Fang(Department of Geriatrics, Dalian Friendship Hospital, Dalian 116000, China)
出处
《中国现代药物应用》
2019年第8期82-83,共2页
Chinese Journal of Modern Drug Application
关键词
老年2型糖尿
利拉鲁肽联
二甲双胍
Senile type 2 diabetes mellitus
Liraglutide
Metformin
